메뉴 건너뛰기




Volumn 60, Issue 2, 2015, Pages 573-581

Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin

Author keywords

Antiviral therapy; Cirrhosis; Hepatitis C; Hepatocellular carcinoma; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

EID: 84922072786     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3361-6     Document Type: Article
Times cited : (37)

References (40)
  • 1
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C: an update
    • COI: 1:CAS:528:DC%2BD1MXkslWjs7o%3D, PID: 19330875
    • Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.
    • (2009) Hepatology. , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3
  • 2
    • 33646852746 scopus 로고    scopus 로고
    • The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
    • PID: 16702586
    • Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.
    • (2006) Ann Intern Med. , vol.144 , pp. 705-714
    • Armstrong, G.L.1    Wasley, A.2    Simard, E.P.3
  • 3
    • 84875054629 scopus 로고    scopus 로고
    • A nationwide seroepidemiology of hepatitis C virus infection in South Korea
    • PID: 23356674
    • Kim do Y, Kim IH, Jeong SH, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int. 2013;33:586–594.
    • (2013) Liver Int , vol.33 , pp. 586-594
    • do Kim, Y.1    Kim, I.H.2    Jeong, S.H.3
  • 4
    • 0036829816 scopus 로고    scopus 로고
    • Natural history of chronic hepatitis C
    • PID: 12407575
    • Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46.
    • (2002) Hepatology. , vol.36 , pp. S35-S46
    • Seeff, L.B.1
  • 5
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    • COI: 1:CAS:528:DC%2BD3MXntF2qtb8%3D, PID: 11583749
    • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965.
    • (2001) Lancet. , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 6
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • COI: 1:CAS:528:DC%2BD38Xnt12rtb0%3D, PID: 12324553
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
    • (2002) N Engl J Med. , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 7
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    • COI: 1:CAS:528:DC%2BD2cXitlOktrg%3D, PID: 14996676
    • Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
    • (2004) Ann Intern Med. , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette, H.2    Morgan, T.R.3
  • 8
    • 78049476361 scopus 로고    scopus 로고
    • A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin
    • COI: 1:CAS:528:DC%2BC3cXhtlKhurrJ, PID: 20637202
    • Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593–1601.
    • (2010) Gastroenterology. , vol.139 , pp. 1593-1601
    • Swain, M.G.1    Lai, M.Y.2    Shiffman, M.L.3
  • 9
    • 62749203302 scopus 로고    scopus 로고
    • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients
    • COI: 1:CAS:528:DC%2BD1MXjvFOnurY%3D, PID: 19072828
    • George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–738.
    • (2009) Hepatology. , vol.49 , pp. 729-738
    • George, S.L.1    Bacon, B.R.2    Brunt, E.M.3
  • 10
    • 0012431804 scopus 로고    scopus 로고
    • Report of the expert committee on the diagnosis and classification of diabetes mellitus
    • Anonymous. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:S5–S20.
    • (2003) Diabetes Care. , vol.26 , pp. S5-S20
    • Anonymous1
  • 11
    • 84864412353 scopus 로고    scopus 로고
    • Revision and update on clinical practice guideline for liver cirrhosis
    • PID: 22511898
    • Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1–21.
    • (2012) Korean J Hepatol. , vol.18 , pp. 1-21
    • Suk, K.T.1    Baik, S.K.2    Yoon, J.H.3
  • 12
    • 0029778988 scopus 로고    scopus 로고
    • An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group
    • COI: 1:STN:280:DyaK28zhvFClug%3D%3D, PID: 8690394
    • Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293.
    • (1996) Hepatology. , vol.24 , pp. 289-293
    • Bedossa, P.1    Poynard, T.2
  • 13
    • 0036733622 scopus 로고    scopus 로고
    • Tchelepi H, Ralls PW, Radin R, et al. Sonography of diffuse liver disease. J Ultrasound Med. 2002;21:1023–1032; quiz 1033-1024
    • Tchelepi H, Ralls PW, Radin R, et al. Sonography of diffuse liver disease. J Ultrasound Med. 2002;21:1023–1032; quiz 1033-1024.
  • 14
    • 79952213055 scopus 로고    scopus 로고
    • Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)
    • COI: 1:CAS:528:DC%2BC3MXkt1Clt78%3D, PID: 21319193
    • Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–894.
    • (2011) Hepatology. , vol.53 , pp. 885-894
    • Jung, K.S.1    Kim, S.U.2    Ahn, S.H.3
  • 15
    • 58149119720 scopus 로고    scopus 로고
    • Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C
    • PID: 18367856
    • Kim KT, Han SY, Kim JH, et al. Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. Korean J Hepatol. 2008;14:36–45.
    • (2008) Korean J Hepatol , vol.14 , pp. 36-45
    • Kim, K.T.1    Han, S.Y.2    Kim, J.H.3
  • 16
    • 84862910095 scopus 로고    scopus 로고
    • Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study
    • COI: 1:CAS:528:DC%2BC38Xmt1ylsbk%3D, PID: 22375178
    • Park SH, Park CK, Lee JW, et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver. 2012;6:98–106.
    • (2012) Gut Liver. , vol.6 , pp. 98-106
    • Park, S.H.1    Park, C.K.2    Lee, J.W.3
  • 17
    • 70349548852 scopus 로고    scopus 로고
    • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    • COI: 1:CAS:528:DC%2BD1MXhtFaju7%2FM, PID: 19749758
    • Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–1104.
    • (2009) Nat Genet. , vol.41 , pp. 1100-1104
    • Suppiah, V.1    Moldovan, M.2    Ahlenstiel, G.3
  • 18
    • 70349966196 scopus 로고    scopus 로고
    • Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
    • COI: 1:CAS:528:DC%2BD1MXhtFentb%2FJ, PID: 19759533
    • Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.
    • (2009) Nature. , vol.461 , pp. 798-801
    • Thomas, D.L.1    Thio, C.L.2    Martin, M.P.3
  • 19
    • 82755197774 scopus 로고    scopus 로고
    • Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin
    • COI: 1:CAS:528:DC%2BC3MXhsVOltLvN, PID: 21907615
    • Lyoo K, Song MJ, Hur W, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol. 2011;52:363–366.
    • (2011) J Clin Virol. , vol.52 , pp. 363-366
    • Lyoo, K.1    Song, M.J.2    Hur, W.3
  • 20
    • 84879495637 scopus 로고    scopus 로고
    • Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
    • PID: 23323251
    • Jeong SH, Jung YK, Yang JW, et al. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. Clin Mol Hepatol. 2012;18:360–367.
    • (2012) Clin Mol Hepatol. , vol.18 , pp. 360-367
    • Jeong, S.H.1    Jung, Y.K.2    Yang, J.W.3
  • 21
    • 80052360000 scopus 로고    scopus 로고
    • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients
    • COI: 1:CAS:528:DC%2BC3MXhtlWqsrvK, PID: 21501223
    • Sinn DH, Kim YJ, Lee ST, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol. 2011;26:1374–1379.
    • (2011) J Gastroenterol Hepatol. , vol.26 , pp. 1374-1379
    • Sinn, D.H.1    Kim, Y.J.2    Lee, S.T.3
  • 22
    • 0036830454 scopus 로고    scopus 로고
    • Side effects of therapy of hepatitis C and their management
    • PID: 12407599
    • Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237–S244.
    • (2002) Hepatology. , vol.36 , pp. S237-S244
    • Fried, M.W.1
  • 23
    • 70449711352 scopus 로고    scopus 로고
    • Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C
    • COI: 1:CAS:528:DC%2BD1MXhtlyqtrzN, PID: 19721856
    • Kwon JH, Bae SH, Choi JY, et al. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J Intern Med. 2009;24:203–211.
    • (2009) Korean J Intern Med. , vol.24 , pp. 203-211
    • Kwon, J.H.1    Bae, S.H.2    Choi, J.Y.3
  • 24
    • 33745404151 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea
    • PID: 16565604
    • Lee H, Choi MS, Paik SW, et al. Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea. Korean J Hepatol. 2006;12:31–40.
    • (2006) Korean J Hepatol , vol.12 , pp. 31-40
    • Lee, H.1    Choi, M.S.2    Paik, S.W.3
  • 25
    • 84884988177 scopus 로고    scopus 로고
    • Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
    • PID: 23564522
    • Asahina Y, Tsuchiya K, Nishimura T, et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–1262.
    • (2013) Hepatology. , vol.58 , pp. 1253-1262
    • Asahina, Y.1    Tsuchiya, K.2    Nishimura, T.3
  • 26
    • 84926254753 scopus 로고    scopus 로고
    • Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes
    • Yamashita N, Ohho A, Yamasaki A, et al. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol. 2013.
    • (2013) J Gastroenterol
    • Yamashita, N.1    Ohho, A.2    Yamasaki, A.3
  • 27
    • 84856151318 scopus 로고    scopus 로고
    • Long-term cohort study of chronic hepatitis C according to interferon efficacy
    • COI: 1:CAS:528:DC%2BC38XjtlKnsLg%3D, PID: 21793911
    • Maruoka D, Imazeki F, Arai M, et al. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27:291–299.
    • (2012) J Gastroenterol Hepatol. , vol.27 , pp. 291-299
    • Maruoka, D.1    Imazeki, F.2    Arai, M.3
  • 28
    • 33845927812 scopus 로고    scopus 로고
    • Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea
    • PID: 17191307
    • Kim JH, Han KH, Lee KS, et al. Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. Yonsei Med J. 2006;47:793–798.
    • (2006) Yonsei Med J. , vol.47 , pp. 793-798
    • Kim, J.H.1    Han, K.H.2    Lee, K.S.3
  • 29
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • COI: 1:CAS:528:DC%2BC3MXotVCku7Y%3D, PID: 21696307
    • Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
    • (2011) N Engl J Med. , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 30
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • COI: 1:CAS:528:DC%2BC3MXotVCrsrg%3D, PID: 21696308
    • Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
    • (2011) N Engl J Med. , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 31
    • 80052826527 scopus 로고    scopus 로고
    • Response-guided telaprevir combination treatment for hepatitis C virus infection
    • COI: 1:CAS:528:DC%2BC3MXhtF2mtrrI, PID: 21916639
    • Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–1024.
    • (2011) N Engl J Med. , vol.365 , pp. 1014-1024
    • Sherman, K.E.1    Flamm, S.L.2    Afdhal, N.H.3
  • 32
    • 79953173221 scopus 로고    scopus 로고
    • Boceprevir for untreated chronic HCV genotype 1 infection
    • COI: 1:CAS:528:DC%2BC3MXkt1Chtrc%3D, PID: 21449783
    • Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
    • (2011) N Engl J Med. , vol.364 , pp. 1195-1206
    • Poordad, F.1    McCone, J.2    Bacon, B.R.3
  • 33
    • 79953176289 scopus 로고    scopus 로고
    • Boceprevir for previously treated chronic HCV genotype 1 infection
    • COI: 1:CAS:528:DC%2BC3MXkt1Cht7k%3D, PID: 21449784
    • Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
    • (2011) N Engl J Med. , vol.364 , pp. 1207-1217
    • Bacon, B.R.1    Gordon, S.C.2    Lawitz, E.3
  • 34
    • 77951652616 scopus 로고    scopus 로고
    • Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    • COI: 1:CAS:528:DC%2BC3cXlsFKlu7c%3D, PID: 20346533
    • Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652–657.
    • (2010) J Hepatol. , vol.52 , pp. 652-657
    • Cardoso, A.C.1    Moucari, R.2    Figueiredo-Mendes, C.3
  • 35
    • 38449091418 scopus 로고    scopus 로고
    • Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    • PID: 18025443
    • Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.
    • (2007) Ann Intern Med. , vol.147 , pp. 677-684
    • Veldt, B.J.1    Heathcote, E.J.2    Wedemeyer, H.3
  • 36
    • 33947360829 scopus 로고    scopus 로고
    • Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    • COI: 1:CAS:528:DC%2BD2sXjs1Gktbc%3D, PID: 17326216
    • Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587.
    • (2007) Hepatology. , vol.45 , pp. 579-587
    • Bruno, S.1    Stroffolini, T.2    Colombo, M.3
  • 37
    • 77956635697 scopus 로고    scopus 로고
    • Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    • COI: 1:CAS:528:DC%2BC3cXhtFyitr7P, PID: 20564351
    • Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–844.
    • (2010) Hepatology. , vol.52 , pp. 833-844
    • Morgan, T.R.1    Ghany, M.G.2    Kim, H.Y.3
  • 38
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • PID: 23268517
    • van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.
    • (2012) JAMA. , vol.308 , pp. 2584-2593
    • van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3
  • 39
    • 77049098144 scopus 로고    scopus 로고
    • Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis
    • PID: 20087166
    • Madhoun MF, Fazili J, Bright BC, et al. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci. 2010;339:169–173.
    • (2010) Am J Med Sci. , vol.339 , pp. 169-173
    • Madhoun, M.F.1    Fazili, J.2    Bright, B.C.3
  • 40
    • 77957774891 scopus 로고    scopus 로고
    • Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    • Kawamura Y, Arase Y, Ikeda K, et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med. 2010;123:951–956 e951.
    • Am J Med. 2010;123 , vol.951-956 , pp. e951
    • Kawamura, Y.1    Arase, Y.2    Ikeda, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.